Antiviral therapy has already been widely used in hospitalised Covid-19 patients after being granted emergency-use authorisation earlier this year

Remdesivir was given to Trump when US president was diagnosed with virus earlier this month

The US Food and Drug Administration approved Gilead Sciences’ antiviral therapy remdesivir on Thursday, making it the first drug to obtain formal clearance for treating the coronavirus.

Regulators had granted an emergency-use authorisation for remdesivir earlier this year, and since then the drug has become a widely used therapy in hospitalised Covid-19 patients. It was given to US President Donald Trump this month when he was diagnosed with the virus.

The approval of remdesivir, sold under the brand name Veklury, will allow Gilead to market the drug and talk about its benefits to doctors, nurses, and patients. That could help solidify its position as a go-to medicine for Covid-19 patients even as other drugs for the disease begin to reach the market.

“Veklury is now the first and only approved Covid-19 treatment in the United States,” Gilead said in a statement. While the drug was in short supply initially, Gilead said that the medicine is now widely available in hospitals across the country as manufacturing capacity has rapidly expanded.

The drug has not been proven to reduce deaths from Covid-19. In a World Health Organization trial, the medicine failed to reduce fatalities, according to preliminary results that were posted on preprint servers last week.

Gilead has criticised the WHO study. In a letter posted on the company’s website, Chief Medical Officer Merdad Parsey said the findings do not negate other results.

Shares of Gilead gained 4.1 per cent in trading after the close of regular market hours on Thursday. Analysts estimate that remdesivir will have sales of US$2.17 billion this year, according to 13 surveyed by Bloomberg.

The company said in June that it will charge US hospitals roughly US$3,120 for most patients who need remdesivir.

The approval is based on a US government-sponsored trial involving more than 1,000 hospitalised coronavirus patients that found that those who received the drug recovered about five days faster than those who got a placebo.

The overall side-effect rate was similar to the placebo in the government study. The most common side effects are nausea and elevated liver enzymes, according to the product’s label.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Lebanon braces for UN-backed court’s verdict on assassination of ex-PM

A UN-backed special tribunal investigating the assassination of former Lebanese prime minister Rafiq Hariri 15 years ago is set to deliver its long-awaited verdict on Tuesday. Four members of the Lebanese militant group Hezbollah are charged with conspiracy to carry…

England tiptoes out of lockdown as economy dives

England tentatively began easing its coronavirus lockdown on Wednesday with some people who cannot do their jobs at home urged to return to work, as stark economic data showed the disastrous impact of the pandemic. The worst-hit country in Europe with…

Ryan Seacrest, girlfriend Shayna Taylor call it quits for the third time

Fox News Flash top entertainment and celebrity headlines are here. Check out what’s clicking today in entertainment. Ryan Seacrest and Shayna Taylor are once again going their separate ways — only this time the split is said to be permanent. “Ryan…

Inside the mind of Dominic Cummings

When the prime minister of the day describes you as a “career psychopath”, your chances of preferment in the political world may not seem rosy. When associates of a leading minister refer to you as “that jumped-up oik”, you may…